Sanjiv Lal: Building a More Accessible Future for Regenerative Medicine

The pharmaceutical scientist, entrepreneur, and Regen Therapy co-founder is bringing scientific curiosity, business experience, and personal purpose to a mission that extends beyond discovery: making credible regenerative healthcare more accessible.

For Sanjiv Lal, the promise of healthcare innovation is inseparable from a practical question: what must be built for promising science to create meaningful impact?

It is a question that connects the different chapters of his career. A pharmaceutical scientist, healthcare entrepreneur, investor, and CEO and Co-Founder of Regen Therapy, Lal has spent more than two decades working across pharmaceuticals, biotechnology, molecular genetics, diagnostics, and laboratory sciences. His experience has placed him at the intersection of scientific inquiry and company building, where an idea must eventually meet the demands of research, infrastructure, and real-world execution.

Today, that perspective informs his work in regenerative medicine. His ambition is not simply to participate in an emerging scientific field. It is to help address the gaps that can prevent credible science from becoming better understood, responsibly developed, and more broadly accessible.

A Foundation in Science, a Career in Building

Lal’s professional foundation began at The Ohio State University, where he earned both a Bachelor of Science and a Master of Science in Pharmaceutical Sciences. That education established the scientific grounding for a career that would expand well beyond a single discipline.

He went on to found and scale multiple healthcare and laboratory businesses, including three laboratory companies, with two successful exits. These experiences brought together two distinct responsibilities: understanding the science behind a business and developing the organization capable of supporting it.

Across his career, Lal has worked in fields that approach healthcare from different directions. Pharmaceuticals and biotechnology focus attention on biological mechanisms and development. Diagnostics and laboratory sciences bring questions of measurement, interpretation, and operational consistency into view. Entrepreneurship adds another set of considerations, including how to assemble teams, develop infrastructure, and turn a concept into a functioning enterprise.

Together, these experiences have shaped the perspective he brings to Regen Therapy. For Lal, the business surrounding the science is not an afterthought. It is part of what determines whether that science can move forward responsibly.

When the Search Became Personal

Although Lal’s career was already rooted in healthcare, his interest in regenerative medicine took on a deeper significance after a substantial personal health challenge.

During that period, he found that conventional approaches could only take him so far. His search for additional answers introduced him to regenerative science, along with the questions and inconsistencies surrounding the field.

The experience was not simply an introduction to scientific possibility. It also exposed gaps in access, education, manufacturing consistency, clinical infrastructure, and scientific credibility.

Those observations helped shape the founding thesis behind Regen Therapy. Lal saw a need to consider not only what regenerative science might offer, but also what would be required to evaluate, develop, and support it with greater rigor.

His personal experience gave the work urgency. His scientific and entrepreneurial background gave him a framework for approaching it. Bringing those perspectives together became central to his direction.

Looking Beyond the Cells

A particular focus of Lal’s work today is secretome science and cellular signaling: the complex network of proteins, growth factors, cytokines, chemokines, extracellular vesicles, and other biological signals involved in communication between cells.

He believes that the next evolution of regenerative medicine will require looking beyond cells themselves to better understand the information exchanged between them.

That belief is a direction for investigation, not a claim that every scientific possibility has already been translated into established healthcare applications. Lal’s stated priorities include the characterization, manufacturing, research, and physician education needed to explore this area responsibly.

This distinction matters to his broader vision. Scientific interest alone does not resolve questions about consistency, interpretation, or appropriate use. His focus includes the work required to develop a clearer understanding of the science and the infrastructure around it.

At Regen Therapy, that outlook connects his interest in biological communication with a practical commitment to building. The opportunity, as he sees it, lies in advancing understanding while strengthening the systems needed to support responsible translation into healthcare.

Connecting People Across Disciplines

Lal’s professional interests extend across longevity, diagnostics, mitochondrial health, biotechnology, artificial intelligence, and increasingly personalized healthcare.

Rather than treating these areas as isolated pursuits, he regularly brings together physicians, researchers, founders, investors, and industry leaders. His aim is to encourage collaboration among people whose expertise may be complementary but whose professional worlds do not always overlap.

His broader portfolio reflects that cross-disciplinary approach. Alongside his leadership at Regen Therapy, he is Co-Founder and Partner at Motivant, owner of Beverly Hills Rejuvenation Center, and a Board Advisor to Carl X Dimes. His work also includes involvement with XPRIZE initiatives focused on health and human performance.

These roles connect scientific, entrepreneurial, advisory, and investment perspectives. They also reflect a consistent interest in the people and organizations working on different parts of healthcare’s future.

For Lal, bringing those perspectives into conversation is part of the work itself. Research questions, clinical considerations, operational challenges, and investment decisions all influence what can be built.

A Mission Centered on Access

At the center of Lal’s work is a larger ambition: democratizing regenerative medicine.

He wants to help move credible regenerative science beyond fragmented, expensive, and highly specialized access. His vision is a future in which stronger science, better infrastructure, and broader education make next-generation regenerative healthcare more scalable and accessible.

Importantly, this is a mission he is working toward, not a declaration that the field’s challenges have already been solved. His emphasis remains on the foundations required to make progress responsibly.

Accessibility, in this vision, involves more than availability alone. It also means addressing the educational and operational gaps that can make an emerging field difficult to understand or navigate. Scientific credibility and broader access are not separate ambitions in his approach. They are connected parts of the same goal.

Sanjiv Lal’s story brings together a scientific education, an entrepreneurial track record, and a personal search that sharpened his sense of purpose. Each has contributed to the question now guiding his work: how can promising science be supported well enough to make a meaningful difference?

For him, discovery is the beginning. The next chapter is about building what allows it to matter.